- Education
- BA, Wake Forest University, 1974
- MD, Wake Forest School of Medicine, 1978
- Internship
- Obstetrics & Gynecology, Wake Forest Baptist Medical Center, 1979
- Residency
- Obstetrics & Gynecology, Wake Forest Baptist Medical Center, 1982
- Fellowship
- Mayo Clinic, 1989
- Board Certifications
- American Board of Obstetrics and Gynecology, Obstetrics and Gynecology
- Positions
- Section Chief, Gynecologic Oncology
- Professor, Gynecologic Oncology
- Professor, Urology
- Departments and Affiliations
- Gynecologic Oncology
- Urology
- Comprehensive Cancer Center
Research
- Serum Calcium and Serum Albumin Are Biomarkers That Can Discriminate Malignant from Benign Pelvic Masses. Kelly MG, Winkler SS, Lentz SS, Berliner SH, Swain MF, Skinner HG, Schwartz GG. Cancer Epidemiol. Biomarkers Prev. 2015 Oct; 24(10):1593-8.
- Catumaxomab for the treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: a phase II study. Berek JS, Edwards RP, Parker LP, DeMars LR, Herzog TJ, Lentz SS, Morris RT, Akerley WL, Holloway RW, Method MW, Plaxe SC, Walker JL, Friccius-Quecke H, Krasner CN. Int. J. Gynecol. Cancer. 2014 Nov; 24(9):1583-9.
- Is bilateral lymphadenectomy for midline squamous carcinoma of the vulva always necessary? An analysis from Gynecologic Oncology Group (GOG) 173. Coleman RL, Ali S, Levenback CF, Gold MA, Fowler JM, Judson PL, Bell MC, De Geest K, Spirtos NM, Potkul RK, Leitao MM, Bakkum-Gamez JN, Rossi EC, Lentz SS, Burke JJ, Van Le L, Trimble CL. Gynecol. Oncol. 2013 Feb; 128(2):155-9.
- Lymphatic mapping and sentinel lymph node biopsy in women with squamous cell carcinoma of the vulva: a gynecologic oncology group study. Levenback CF, Ali S, Coleman RL, Gold MA, Fowler JM, Judson PL, Bell MC, De Geest K, Spirtos NM, Potkul RK, Leitao MM, Bakkum-Gamez JN, Rossi EC, Lentz SS, Burke JJ, Van Le L, Trimble CL. J. Clin. Oncol. 2012 Nov; 30(31):3786-91.
- A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group study. Coleman RL, Brady WE, McMeekin DS, Rose PG, Soper JT, Lentz SS, Hoffman JS, Shahin MS. Gynecol. Oncol. 2011 Jul; 122(1):111-5.